Get the Stockscreener App
60.66
5.34%
2.99
Guardant Health Inc stock is traded at $60.66, with a volume of 1.94M.
It is up +5.34% in the last 24 hours and down -1.83% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$57.67
Open:
$59.37
24h Volume:
1.94M
Relative Volume:
0.80
Market Cap:
$7.56B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-14.31
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+3.32%
1M Performance:
-1.83%
6M Performance:
+30.76%
1Y Performance:
+172.42%
1-Day Range:
$58.73
$63.05
1-Week Range:
$55.38
$63.05
52-Week Range:
$20.14
$68.00
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
60.60 | 7.45B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
460.64 | 177.38B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
181.02 | 135.85B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
615.12 | 51.87B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.68 | 35.70B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
177.07 | 31.70B | 15.70B | 1.24B | 2.01B | 6.91 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health (NASDAQ:GH) Shares Gap Up Following Analyst Upgrade - MarketBeat
Quest Diagnostics and Guardant Health collaborate for blood-based cancer screening - ROI-NJ
GH: Guggenheim Raises Price Target for Guardant Health to $67 | - GuruFocus
JP Morgan Maintains "Overweight" Rating for Guardant Health (GH) - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - MarketBeat
Guggenheim Issues Positive Forecast for Guardant Health (NASDAQ:GH) Stock Price - MarketBeat
Guardant Health (NASDAQ:GH) Rating Increased to Outperform at Wolfe Research - MarketBeat
Wolfe Research lifts Guardant Health to Outperform, sees 30% upside By Investing.com - Investing.com Canada
Guardant Health (GH) Sees Analyst BTIG Raise Price Target to $80 - GuruFocus
Wolfe Research Upgrades Guardant Health to Outperform From Peer Perform, Price Target is $75 - MarketScreener
Guardant Health (GH) Upgraded to Outperform by Wolfe Research - GuruFocus
Guardant Health Hosts Investor Day in NYC - TipRanks
Guardant Health and Quest partner to expand blood-based cancer test - Investing.com Canada
Guardant Health and Quest partner to expand blood-based cancer test By Investing.com - Investing.com South Africa
Guardant joins Quest to widen access to Shield (GH:NASDAQ) - Seeking Alpha
Guardant Health (NASDAQ:GH) Shares Down 4%What's Next? - MarketBeat
Guardant Health (GH) Partners with Quest Diagnostics for Blood T - GuruFocus
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States - Yahoo Finance
United States Liquid Biopsy Market Set for Breakthrough Growth - openPR.com
Strs Ohio Purchases New Stake in Guardant Health, Inc. $GH - MarketBeat
3 Reasons to Avoid GH and 1 Stock to Buy Instead - Yahoo Finance
Guardant Health (GH) Stock Is Up, What You Need To Know - TradingView
Guardant Health stock rating reiterated as Buy by UBS ahead of Analyst Day - Investing.com
UPC sees next life sciences case as Guardant sues Sophia Genetics - JUVE Patent
CCORF Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
Guardant Health (NASDAQ:GH) Raised to "Strong-Buy" at Wells Fargo & Company - MarketBeat
BTIG reiterates Buy rating on Guardant Health stock ahead of Analyst Day - Investing.com Canada
Wells Fargo Initiates Coverage on Guardant Health (GH) with Over - GuruFocus
BTIG Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Guardant Health (NASDAQ:GH) Given Buy Rating at BTIG Research - MarketBeat
BTIG Reiterates 'Buy' Rating for Guardant Health (GH) | GH Stock News - GuruFocus
Aug Sectors: Is Guardant Health Inc. impacted by rising ratesWeekly Trend Recap & Risk Controlled Daily Plans - خودرو بانک
Intech Investment Management LLC Boosts Position in Guardant Health, Inc. $GH - MarketBeat
VA Extends Coverage for Revolutionary Blood-Based Colorectal Cancer Screening Test - Goldsboro Daily News
RSI Check: How does Guardant Health Inc compare to its peersTrade Risk Report & Expert Verified Movement Alerts - خودرو بانک
Guardant Health, Inc. (NASDAQ:GH) Receives $58.24 Consensus Target Price from Analysts - MarketBeat
VIX Spike: Does Modine Manufacturing Company have a sustainable dividendCPI Data & Stepwise Entry and Exit Trade Signals - khodrobank.com
US Market Wrap: Is now the right time to enter Guardant Health IncBuy Signal & Daily Stock Trend Reports - خودرو بانک
Medina Manuel Hidalgo Sells 2,165 Shares of Guardant Health (NASDAQ:GH) Stock - MarketBeat
Guardant Health Inc. (GH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Rankings: Can Guardant Health Inc navigate macro headwindsJuly 2025 News Drivers & Long-Term Growth Plans - khodrobank.com
Market Outlook: Can Guardant Health Inc. maintain sales growthWeekly Trend Summary & Weekly Momentum Stock Picks - خودرو بانک
Testing & Diagnostics Services Q2 Earnings: Guardant Health (NASDAQ:GH) is the Best in the Biz - Yahoo Finance
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 164,263 Shares of Guardant Health, Inc. $GH - MarketBeat
RSI Check: Can Guardant Health Inc. be recession proof2025 EndofYear Setup & Risk Managed Investment Entry Signals - khodrobank.com
Q2 Earnings Recap: Guardant Health (NASDAQ:GH) Tops Testing & Diagnostics Services Stocks - Yahoo Finance
Guardant Health (GH) director Potter sells $1446 in stock By Investing.com - Investing.com Australia
Guardant Health (GH) director Potter sells $1446 in stock - Investing.com
Jobs Data: Can Guardant Health Inc maintain its current growth rateQuarterly Profit Report & Real-Time Volume Spike Alerts - خودرو بانک
Aug Update: What is the implied volatility of Guardant Health IncPortfolio Gains Summary & Daily Market Momentum Tracking - خودرو بانک
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):